BLOG

Developing IL-15 superagonists for cancer therapy

In this article, Drug Target Review’s Hannah Balfour discusses with Chief Medical Officer of SOTIO, Richard Sachse, why interleukin 15 (IL-15) signalling has become a top target for cancer immunotherapies and how they designed their drug (SO-C101) to overcome some of the limitations of previous IL-15 and IL-2 targeted therapies.